Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) EBITDA (2016 - 2025)

Regen BioPharma (RGBP) has disclosed EBITDA for 13 consecutive years, with -$123055.0 as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 44.09% to -$123055.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$338540.0, a 18.86% increase, with the full-year FY2025 number at -$338540.0, up 18.86% from a year prior.
  • EBITDA was -$123055.0 for Q3 2025 at Regen BioPharma, down from -$40758.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$12973.0 in Q1 2021 to a low of -$463867.0 in Q4 2022.
  • A 5-year average of -$103400.5 and a median of -$85402.0 in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 570.72% in 2021, then skyrocketed 73.53% in 2023.
  • Regen BioPharma's EBITDA stood at -$106422.0 in 2021, then tumbled by 335.88% to -$463867.0 in 2022, then skyrocketed by 73.53% to -$122782.0 in 2023, then surged by 50.01% to -$61378.0 in 2024, then tumbled by 100.49% to -$123055.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's EBITDA are -$123055.0 (Q3 2025), -$40758.0 (Q2 2025), and -$113349.0 (Q1 2025).